Le Lézard
Classified in: Health
Subjects: CCA, FVT

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024


DUBLIN, Feb. 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 15, 2024 to discuss the company's fourth quarter and year-end 2023 financial results. Management will also discuss financial expectations for 2024 and provide an update on the company.

The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. 

About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

Alkermes plc Logo

Logo - https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg


These press releases may also interest you

at 10:20
Todd Clegg Named Carestream's Chief Executive Officer
Carestream, a world-leading provider of medical imaging systems and non-destructive testing solutions, announced that Todd Clegg has been named CEO and appointed to the Board of Directors, effective immediately. Mr. Clegg joined Carestream in...

at 10:19
FDA Takes Action Aimed at Helping to Ensure the Safety and Effectiveness of Laboratory Developed Tests
Today, the U.S. Food and Drug Administration took action aimed at helping to ensure the safety and effectiveness of laboratory developed tests, or LDTs, which are used in a growing number of health care decisions and about which concerns have been...

at 10:15
Nearly Two-Thirds of People on Weight Loss Drugs Stop Due to Side Effects, Other Concerns
The majority of patients prescribed weight loss drugs for obesity stop taking them because of side effects and cost, according to the results of a new survey from HealthCentral, a leading digital platform focused on informing and empowering people...

at 10:07
Integral Hires Five New Principals in Key Areas of Health, Engineering, and Sustainability
Integral Consulting continues to invest in its people and expand across practice areas to meet increasing demands of legal, industrial, and government clients. With five new Principals recently added to our team, we further our commitment to address...

at 10:01
Sage Growth Unveils Brand Refresh to Reflect National Scope and Impact of Firm
Sage Growth Partners (SGP), a healthcare growth strategy and marketing firm, today announced the completion of a comprehensive brand refresh, showcasing a new logo and website that underscore the company's expanding influence, client roster, and...

at 10:00
Cold Spring Harbor Laboratory and Northwell Health extend strategic affiliation
Leaders from two of New York's preeminent bioscience and healthcare institutions came together at Carnegie Hall to acknowledge the signing of an update to their affiliation agreement initiated in 2015. The Cold Spring Harbor Laboratory-Northwell...

More news about Health...


News published on and distributed by: